Sugi Predict

Sugi Predict / Compounds / SCHEMBL7062473

SCHEMBL7062473

SCHEMBL7062473

COC(=O)c1ccc(O)cc1Br

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 6/20 0.67
▸ CA1 P00915 6/20 0.67
▸ CA2 P00918 6/20 0.67
▸ CA7 P43166 6/20 0.67
▸ CA9 Q16790 6/20 0.67
▸ CA14 Q9ULX7 6/20 0.67
▸ PDK2 Q15119 1/20 0.67
▸ PDK4 Q16654 1/20 0.67
▸ GAA P10253 2/20 0.49
▸ EGFR P00533 2/20 0.47
▸ LMNA P02545 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ KDM4E B2RXH2 2/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ MAPT P10636 2/20 0.44
▸ HPGD P15428 2/20 0.44
▸ HSD17B10 Q99714 2/20 0.44
▸ GLA P06280 1/20 0.44
▸ CASP1 P29466 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22749357 0.93 CA12 (0.59) CA12CA1CA2CA7CA9
SCHEMBL22749359 0.89 CA12 (0.54) CA12CA1CA2CA7CA9
SCHEMBL177377 0.85 CA12 (0.67) CA12CA1CA2CA7CA9
SCHEMBL30121064 0.85 CA12 (0.67) CA12CA1CA2CA7CA9
SCHEMBL3839211 0.82 NR4A2 (0.54) CA12CA1CA2CA7CA9
SCHEMBL158999 0.82 CA12 (0.74) CA12CA1CA2CA7CA9
SCHEMBL2305885 0.81 KDM4E (0.57) CA12CA1CA2CA7CA9
SCHEMBL1770905 0.81 NR4A2 (0.50) CA12CA1CA2CA7CA9
SCHEMBL70233 0.81 KDM4E (0.62) CA12CA1CA2CA7CA9
SCHEMBL22833376 0.80 CA12 (0.70) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026107424-A1 N-(4-(IMIDAZO[4,5-B]PYRIDIN-5-YL)-2-PYRIDYL)BENZAMIDE DERIVATIVES AS CAMK2 INHIBITORS FOR THE TREATMENT OF HEART FAILURE BRISTOL-MYERS SQUIBB COMPANY (US) 2026-05-21 — — WO disclosed
US-12630510-B2 EP2 antagonist ONO PHARMACEUTICAL CO., LTD. (JP) 2026-05-19 — — US disclosed
EP-3992176-B1 EP2 ANTAGONIST ONO PHARMACEUTICAL CO (JP) 2025-08-27 — — EP disclosed
US-20250154163-A1 Pyrimidinone-Containing 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors ENANTA PHARMACEUTICALS, INC. 2025-05-15 — — US disclosed
WO-2025090868-A1 PYRIMIDINONE-CONTAINING 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2025-05-01 — — WO disclosed
WO-2024178390-A1 COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2024-08-29 — — WO disclosed
WO-2023192989-A2 PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS AZKARRA THERAPEUTICS, INC. (US) 2023-10-05 — — WO disclosed
WO-2023192989-A2 PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS AZKARRA THERAPEUTICS, INC. (US) 2023-10-05 — — WO disclosed
US-20220388955-A1 EP2 ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 2022-12-08 — — US disclosed
WO-2022138793-A1 COMBINATION BETWEEN EP2 RECEPTOR ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR AND/OR EP4 RECEPTOR ANTAGONIST 小野薬品工業株式会社 2022-06-30 — — WO disclosed
US-20140256725-A1 FSH RECEPTOR ANTAGONISTS MERCK SHARP & DOHME B.V. (NL) 2014-09-11 — — US disclosed
US-20140256817-A1 AMPHIPATHIC AND OTHER DOUBLE-SIDED ALPHA-HELIX MIMETICS BASED ON A 1,2-DIPHENYLACETYLENE SCAFFOLD UNIVERSITY OF MARYLAND, BALTIMORE (US) 2014-09-11 — — US disclosed
WO-2013041461-A1 FSH RECEPTOR ANTAGONISTS MSD OSS B.V. (NL) 2013-03-28 — — WO disclosed
CN-101189248-A Novel phosphorus-containing thyromimetics METABASIS THERAPEUTICS INC (US) 2008-05-28 — — CN disclosed
CN-1882327-A Novel phosphorus-containing thyromimetics METABASIS THERAPEUTICS INC (US) 2006-12-20 — — CN disclosed
CN-1227231-C Ether and amide compounds as medicide for treating glycuresis and preparing process thereof KOTOBUKI SEIYAKU CO LTD (JP) 2005-11-16 — — CN disclosed
EP-1313696-A2 AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS ABBOTT LABORATORIES (US) 2003-05-28 — — EP disclosed
US-20020035137-A1 Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors ABBOTT LABORATORIES 2002-03-21 — — US disclosed
WO-2002018323-A2 AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS ABBOTT LABORATORIES (US) 2002-03-07 — — WO disclosed
CN-1311767-A Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders KAROBIO AB (SE) 2001-09-05 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256725-A1 FSH RECEPTOR ANTAGONISTS FSHR, GNRHR, LHCGR CA12 2950/4885CA1 3275/4885CA2 2600/4885
US-20020035137-A1 Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors PPM1A, PTPRO, PTP4A1 CA12 3216/4885CA1 895/4885CA2 824/4885
US-20220388955-A1 EP2 ANTAGONIST PTGER2, PTGER1, PTGES2 CA12 3357/4885CA1 3812/4885CA2 764/4885
US-20140256817-A1 AMPHIPATHIC AND OTHER DOUBLE-SIDED ALPHA-HELIX MIMETICS BASED ON A 1,2-DIPHENYLACETYLENE SCAFFOLD SIN3A, ERH, AIP CA12 3801/4885CA1 3125/4885CA2 3438/4885
US-12630510-B2 EP2 antagonist PTGER2, PTGER1, PTGER4 CA12 1550/4885CA1 1466/4885CA2 521/4885
US-20250154163-A1 Pyrimidinone-Containing 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors HSD17B13, HSD17B1, HSD11B1 CA12 3600/4885CA1 3812/4885CA2 4064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.